Format

Send to

Choose Destination
Int J Cancer. 2019 Jan 15;144(2):380-388. doi: 10.1002/ijc.31849. Epub 2018 Nov 13.

Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria.

Author information

1
Department of Urology, College of Medicine, Chungbuk National University, Cheongju, South Korea.
2
Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, South Korea.
3
Department of Urology, School of Medicine, Kyungpook National University, Daegu, South Korea.
4
Department of Urology, Kyungpook National University Hospital, Daegu, South Korea.
5
Department of Business Data Convergence, Chungbuk National University, Cheongju, South Korea.
6
Theragen Etex Bio Institute, Suwon, 443-270, South Korea.
7
Department of Urology, Eulji University Hospital, Daejeon, South Korea.
8
Section of Urologic Oncology and Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
9
Department of Food Science and Technology, Chung-Ang University, Ansung, 456-756, South Korea.
10
Department of Biochemistry, College of Oriental Medicine, Dong-Eui University, Busan, South Korea.
11
Department of Biomedical Engineering, Chungbuk National University College of Medicine, Cheongju, South Korea.

Abstract

The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under nonmalignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria. A multicenter study was performed using 543 urine samples obtained from the National Biobank of Korea, including 326 BC, 174 hematuria and 43 pyuria without cancer. The urinary miR-6124 to miR-4511 ratio was considerably higher in BC than in hematuria or pyuria, and enabled the discrimination of BC from patients with hematuria at a sensitivity of >90% (p < 0.001). Conclusively, the proposed noninvasive diagnostic tool based on the expression ratio of urinary cell-free miR-6124 to miR-4511 can reduce unnecessary cystoscopies in patients with hematuria undergoing evaluation for BC, with a minimal loss in sensitivity for detecting cancer.

KEYWORDS:

bladder cancer; hematuria; miRNA; noninvasive biomarker

PMID:
30183088
DOI:
10.1002/ijc.31849
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center